Affymax, Takeda Gain Exposure on Supplier Deal for OMONTYS

Affymax, Inc. (AFFY) gapped up 10% this morning with the announcement of a major supply agreement between Takeda Pharmaceuticals (TKPYY), Affymax, and Fresenius Medical Care North America (NYSE:FMS), on their once-monthly injectable anemia treatment. OMONTYS, a collaboration product from Takeda and Affymax approved in March, is indicated specifically in treating dialysis patients suffering from anemia and is the only once-monthly treatment on the market. As one of the largest dialysis suppliers and operators in North America, Fresenius plans to introduce the injectable into 100 patient centers within the next few weeks and evaluate results for broader implementation. Although the announcement does not indicate the financials of the agreement, AFFY is trending towards above-average volume for the day.